hepatic stiffness
In the present study, FIB‐4 scores were calculable in 25 patients belonging to the Italian cohort with baseline and follow‐up data on platelet levels and transaminases, ALT and AST. FIB‐4 results showed no significant increase in mean FIB‐4 scores from baseline for up to 110.4 months (>9 years; exposure range 1.4–110.4 months, median exposure 31.3 months; Figure FIB‐4 scores by months of treatment with lomitapide in patients with baseline and follow‐up data (One patient (patient 1) had elevated baseline and follow‐up FIB‐4 scores >2.67 (4.78 and 4.37, respectively). A further patient (patient 7) with an elevated baseline FIB‐4 score of 2.20 showed a modest increase to >2.67 (2.79) at follow‐up. In these two cases, the patients were > 65 years old (77 and 66 years old, respectively; Figure Patient 16 also had elevated baseline and follow‐up FIB‐4 scores >2.67 (3.12 and 4.65, respectively; Figure In all cases, elevated FIB‐4 scores were set against a background of normal liver transaminases. For patients 7 and 16, FIB scores >2.67 were associated with normal hepatic stiffness measured by elastography <7.0 kPa (Table 